ECSP066431A - Moléculas de unión de nogo-a y uso farmacéutico de las mismas - Google Patents
Moléculas de unión de nogo-a y uso farmacéutico de las mismasInfo
- Publication number
- ECSP066431A ECSP066431A EC2006006431A ECSP066431A ECSP066431A EC SP066431 A ECSP066431 A EC SP066431A EC 2006006431 A EC2006006431 A EC 2006006431A EC SP066431 A ECSP066431 A EC SP066431A EC SP066431 A ECSP066431 A EC SP066431A
- Authority
- EC
- Ecuador
- Prior art keywords
- binding molecule
- nogo
- human
- same
- pharmaceutical use
- Prior art date
Links
- 210000005036 nerve Anatomy 0.000 abstract 2
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000010494 dissociation reaction Methods 0.000 abstract 1
- 230000005593 dissociations Effects 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invención proporciona una molécula de unión que es capaz de unirse al polipéptido NogoA humano o NiG humano o NiG-D20 humano o NogoA_342-357 humano, con una constante de disociación de <1000 nM, un polipéptido que codifica dicha molécula de unión; un vector de expresión que comprende dicho polinucleótido; un sistema de expresión que comprende un polinucleótido capaz de producir una molécula de unión; una célula huésped aislada que comprende un sistema de expresión según se define anteriormente; el uso de tal molécula de unión como un farmacéutico, especialmente en el tratamiento de reparación de nervios; una composición farmacéutica que comprende dicha molécula de unión; y un método de tratamiento de enfermedades asociadas con la reparación de nervios.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0321997.9A GB0321997D0 (en) | 2003-09-19 | 2003-09-19 | Organic compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP066431A true ECSP066431A (es) | 2006-09-18 |
Family
ID=29266310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2006006431A ECSP066431A (es) | 2003-09-19 | 2006-03-17 | Moléculas de unión de nogo-a y uso farmacéutico de las mismas |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US20090181023A1 (es) |
| EP (3) | EP1668033A2 (es) |
| JP (1) | JP2007527232A (es) |
| KR (1) | KR20060119982A (es) |
| CN (1) | CN1878792A (es) |
| AR (1) | AR045671A1 (es) |
| AU (2) | AU2004274164B2 (es) |
| BR (1) | BRPI0414174B8 (es) |
| CA (1) | CA2538725C (es) |
| CO (1) | CO5680457A2 (es) |
| EC (1) | ECSP066431A (es) |
| GB (1) | GB0321997D0 (es) |
| IL (2) | IL174145A (es) |
| IS (1) | IS8404A (es) |
| MA (1) | MA28088A1 (es) |
| MY (2) | MY161068A (es) |
| NO (1) | NO20061678L (es) |
| NZ (1) | NZ545679A (es) |
| PE (1) | PE20050949A1 (es) |
| RU (1) | RU2380377C2 (es) |
| SG (1) | SG146660A1 (es) |
| TN (1) | TNSN06085A1 (es) |
| TW (1) | TWI372060B (es) |
| WO (1) | WO2005028508A2 (es) |
| ZA (1) | ZA200601842B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR048912A1 (es) * | 2003-12-22 | 2006-06-14 | Glaxo Group Ltd | Inmunoglobulinas anti-nogo |
| SG157418A1 (en) * | 2004-12-01 | 2009-12-29 | Univ Singapore | Nogo a protein fragments as neuronal network- interacting peptides |
| EP1899377B1 (en) * | 2005-07-05 | 2012-08-22 | Glaxo Group Limited | Humanised antibodies specific for nogo-a and phrarmaceutical uses thereof |
| GB0525662D0 (en) | 2005-12-16 | 2006-01-25 | Glaxo Group Ltd | Immunoglobulins |
| PL2207808T3 (pl) | 2007-11-02 | 2013-11-29 | Novartis Ag | Ulepszone cząsteczki wiążące się z Nogo-A i ich zastosowania farmaceutyczne |
| US8828390B2 (en) | 2010-07-09 | 2014-09-09 | Universitat Zurich | Uses of NOGO-A inhibitors and related methods |
| CA2876284A1 (en) | 2012-07-05 | 2014-01-09 | Glaxo Group Limited | Optimum dose regime of an anti-nogo-a antibody in the treatment of amyotrophic lateral sclerosis |
| CN113527462B (zh) * | 2020-04-22 | 2023-05-23 | 北京大学 | 一种具有镇痛作用的小分子肽及其特异性抗体 |
| CN114470197B (zh) * | 2022-02-16 | 2023-10-03 | 天津长和生物技术有限公司 | 低氧培养的hUCMSC联合NogoA抗体在脊髓损伤治疗中的应用 |
| CN119768424A (zh) * | 2022-08-22 | 2025-04-04 | 舒泰神（北京）生物制药股份有限公司 | 特异性识别Nogo-A的抗体及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308573D0 (en) | 1983-03-29 | 1983-05-05 | British Nuclear Fuels Ltd | Filament impregnating/coating |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| ATE87659T1 (de) | 1986-09-02 | 1993-04-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| JP2904918B2 (ja) | 1989-02-13 | 1999-06-14 | シェーリング アクチェンゲゼルシャフト | 新規血栓溶解剤 |
| WO2000005364A1 (en) * | 1998-07-22 | 2000-02-03 | Smithkline Beecham Plc | Protein similar to neuroendrocrine-specific protein, and encoding cdna |
| SK9992002A3 (en) * | 2000-01-12 | 2003-05-02 | Univ Yale | Nogo receptor-mediated blockade of axonal growth |
| EP2298717B1 (en) * | 2001-11-30 | 2015-10-28 | Biogen MA Inc. | Antibodies against monocyte chemotactic proteins |
| GB0228832D0 (en) * | 2002-12-10 | 2003-01-15 | Novartis Ag | Organic compound |
| AR048912A1 (es) * | 2003-12-22 | 2006-06-14 | Glaxo Group Ltd | Inmunoglobulinas anti-nogo |
-
2003
- 2003-09-19 GB GBGB0321997.9A patent/GB0321997D0/en not_active Ceased
-
2004
- 2004-09-16 AR ARP040103334A patent/AR045671A1/es unknown
- 2004-09-17 NZ NZ545679A patent/NZ545679A/en not_active IP Right Cessation
- 2004-09-17 PE PE2004000908A patent/PE20050949A1/es not_active Application Discontinuation
- 2004-09-17 RU RU2006112849/13A patent/RU2380377C2/ru active
- 2004-09-17 US US10/572,434 patent/US20090181023A1/en not_active Abandoned
- 2004-09-17 CA CA2538725A patent/CA2538725C/en not_active Expired - Fee Related
- 2004-09-17 TW TW093128254A patent/TWI372060B/zh not_active IP Right Cessation
- 2004-09-17 EP EP04765380A patent/EP1668033A2/en not_active Withdrawn
- 2004-09-17 WO PCT/EP2004/010489 patent/WO2005028508A2/en not_active Ceased
- 2004-09-17 EP EP10160905A patent/EP2248827A1/en not_active Withdrawn
- 2004-09-17 KR KR1020067005424A patent/KR20060119982A/ko not_active Ceased
- 2004-09-17 MY MYPI2013003188A patent/MY161068A/en unknown
- 2004-09-17 JP JP2006526602A patent/JP2007527232A/ja active Pending
- 2004-09-17 MY MYPI20043786A patent/MY158078A/en unknown
- 2004-09-17 CN CNA2004800332675A patent/CN1878792A/zh active Pending
- 2004-09-17 SG SG200806933-8A patent/SG146660A1/en unknown
- 2004-09-17 AU AU2004274164A patent/AU2004274164B2/en not_active Ceased
- 2004-09-17 EP EP10176103A patent/EP2423225A3/en not_active Withdrawn
- 2004-09-17 BR BRPI0414174A patent/BRPI0414174B8/pt not_active IP Right Cessation
-
2006
- 2006-03-03 ZA ZA200601842A patent/ZA200601842B/en unknown
- 2006-03-06 IL IL174145A patent/IL174145A/en active IP Right Grant
- 2006-03-17 TN TNP2006000085A patent/TNSN06085A1/en unknown
- 2006-03-17 EC EC2006006431A patent/ECSP066431A/es unknown
- 2006-03-29 CO CO06031001A patent/CO5680457A2/es active IP Right Grant
- 2006-04-07 MA MA28921A patent/MA28088A1/fr unknown
- 2006-04-10 IS IS8404A patent/IS8404A/is unknown
- 2006-04-12 NO NO20061678A patent/NO20061678L/no not_active Application Discontinuation
-
2009
- 2009-01-22 AU AU2009200237A patent/AU2009200237B2/en not_active Ceased
- 2009-12-28 IL IL203007A patent/IL203007A/en active IP Right Grant
-
2010
- 2010-06-16 US US12/816,964 patent/US20110008334A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2009000190A1 (en) | Lingo binding molecules and pharmaceutical use thereof | |
| BRPI0413728B8 (pt) | muteína da lipocalina da lágrima humana, métodos para geração e para produção de muteína, composição farmacêutica e uso de muteína | |
| CY1110848T1 (el) | Αντισωμα αντι ανθρωπου νοgo α kai h φαρμακευτικη του χρηση | |
| ATE382053T1 (de) | System zur antikörperexpression und- synthese | |
| EE05075B1 (et) | POL1212 aminohappejrjestust kodeeriv DNA, seda sisaldav ekspressioonivektor, sea modifitseeritud VIII-tegur, sellel p?hinev ravimkompositsioon ning meetod sea modifitseeritud VIII-teguri aminohappejrjestust omava valgu valmistamiseks | |
| EA200801509A1 (ru) | Человеческие моноклональные антитела к протеинтирозинкиназе 7 ( ptk7) и способы применения антител против ptk7 | |
| EA200800229A1 (ru) | Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) | |
| BRPI0413022A (pt) | derivados de 3-amino cromado e 2-amino tetralina | |
| ECSP066431A (es) | Moléculas de unión de nogo-a y uso farmacéutico de las mismas | |
| NO20071378L (no) | Tiazolo-naftylsyrer. | |
| GB0327380D0 (en) | Method | |
| AR072934A1 (es) | Moleculas aglutinantes de nogo-a y uso farmaceutico de las mismas | |
| NO20055741D0 (no) | Nye kjemiske forbindelser | |
| TH71697A (th) | โมเลกุลสำหรับจับ nogo-a และการใช้สารเหล่านี้ในทางยา |